CY1111677T1 - Διαγνωση και προγνωση ασθενων με καρκινο μαστου - Google Patents

Διαγνωση και προγνωση ασθενων με καρκινο μαστου

Info

Publication number
CY1111677T1
CY1111677T1 CY20111100596T CY111100596T CY1111677T1 CY 1111677 T1 CY1111677 T1 CY 1111677T1 CY 20111100596 T CY20111100596 T CY 20111100596T CY 111100596 T CY111100596 T CY 111100596T CY 1111677 T1 CY1111677 T1 CY 1111677T1
Authority
CY
Cyprus
Prior art keywords
breast cancer
relates
diagnosis
whose expression
prognosis
Prior art date
Application number
CY20111100596T
Other languages
English (en)
Inventor
Hongyue Dai
Yudong He
Peter S Linsley
Mao Mao
Christopher J Roberts
Veer Laura Johanna Van´T
De Vijver Marc J Van
Rene Bernards
A A M Hart
Original Assignee
The Netherlands Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Netherlands Cancer Institute filed Critical The Netherlands Cancer Institute
Publication of CY1111677T1 publication Critical patent/CY1111677T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Η παρούσα εφεύρεση αφορά γενετικούς δείκτες η έκφραση των οποίων συσχετίζεται με τον καρκίνο του μαστού. Ειδικά, η εφεύρεση παρέχει ομάδες δεικτών των οποίων το πρότυπα έκφρασης μπορεί να χρησιμοποιηθούν για να διαφοροποιήσουν κλινικές καταστάσεις που συνδυάζονται με καρκίνο μαστού, όπως την παρουσία ή απουσία υποδοχέα οιστρογόνου ESR1 και BRCA1 και σποραδικών όγκων και για να παρέχουν πληροφόρηση επί της πιθανότητας μελλοντικών μεταστάσεων από τον όγκο εντός πέντε ετών από την αρχική διάγνωση. Η εφεύρεση αφορά μεθόδους χρήσης αυτών των δεικτών για να διακρίνονται αυτές οι καταστάσεις. Η εφεύρεση επίσης αφορά κιτ που περιέχουν έτοιμες-για-χρήση μικροδέσμες και λογισμικό υπολογιστή για ανάλυση δεδομένων χρησιμοποιώντας τις στατιστικές μεθόδους που αποκαλύπτονται εδώ.
CY20111100596T 2001-06-18 2011-06-23 Διαγνωση και προγνωση ασθενων με καρκινο μαστου CY1111677T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29891801P 2001-06-18 2001-06-18
US38071002P 2002-05-14 2002-05-14
EP02746538A EP1410011B1 (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients

Publications (1)

Publication Number Publication Date
CY1111677T1 true CY1111677T1 (el) 2015-10-07

Family

ID=26970946

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100596T CY1111677T1 (el) 2001-06-18 2011-06-23 Διαγνωση και προγνωση ασθενων με καρκινο μαστου

Country Status (11)

Country Link
US (5) US7514209B2 (el)
EP (1) EP1410011B1 (el)
JP (2) JP2005500832A (el)
AT (1) ATE503023T1 (el)
AU (1) AU2002316251A1 (el)
CA (1) CA2451074C (el)
CY (1) CY1111677T1 (el)
DE (1) DE60239535D1 (el)
DK (1) DK1410011T3 (el)
PT (1) PT1410011E (el)
WO (1) WO2002103320A2 (el)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241728A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of lung disease related gene transcripts in blood
US20060134635A1 (en) * 2001-02-28 2006-06-22 Chondrogene Limited Method for the detection of coronary artery disease related gene transcripts in blood
US20040265868A1 (en) * 1999-01-06 2004-12-30 Chondrogene Limited Method for the detection of depression related gene transcripts in blood
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20040248169A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US20030216558A1 (en) * 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
NZ573831A (en) * 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
US20030180747A1 (en) * 2001-10-11 2003-09-25 Hruban Ralph H. Pancreatic cancer diagnosis and therapies
US20040009495A1 (en) * 2001-12-07 2004-01-15 Whitehead Institute For Biomedical Research Methods and products related to drug screening using gene expression patterns
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
CN1643163A (zh) * 2002-02-20 2005-07-20 Ncc技术投资私人有限公司 关于癌症诊断的材料和方法
EP3115470B1 (en) 2002-03-13 2018-07-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
CA2485373A1 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US20040091486A1 (en) * 2002-05-10 2004-05-13 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
JP4606879B2 (ja) 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
JP2006515515A (ja) * 2002-12-20 2006-06-01 アバロン ファーマシューティカルズ，インコーポレイテッド 診断および治療スクリーニングに有用な増幅癌標的遺伝子
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516138A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
JP4568716B2 (ja) * 2003-02-20 2010-10-27 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を測定するためのイントロンｒｎａの使用
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
WO2004091375A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20070134660A1 (en) * 2003-05-30 2007-06-14 Rosetta Inpharmatics Llc Methods for identifying modulators of kinesin activity
CA2528549A1 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
EP3470535B1 (en) 2003-06-24 2020-04-01 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050112622A1 (en) 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
PL1668152T3 (pl) * 2003-08-28 2009-06-30 Ipsogen Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
BRPI0414553A (pt) * 2003-09-19 2006-11-07 Arcturus Bioscience Inc previsão do resultado de tratamento contra o cáncer de mama
US9856533B2 (en) * 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
GB0323226D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer diagnosis
EP1522594A3 (en) * 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005064019A2 (en) 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
MXPA06009545A (es) * 2004-02-20 2007-03-07 Johnson & Johnson Pronosticos del cancer de mama.
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2558808A1 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
EP1756308A1 (en) * 2004-04-23 2007-02-28 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
KR20070057761A (ko) * 2004-06-04 2007-06-07 아비아라디엑스, 인코포레이티드 종양의 확인방법
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006012522A1 (en) 2004-07-23 2006-02-02 Pacific Edge Biotechnology Ltd. Urine markers for detection of bladder cancer
AU2005267756A1 (en) * 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
EP1627923A1 (en) * 2004-08-18 2006-02-22 Het Nederlands Kanker Instituut Means and methods for detecting and/or staging a follicular lymphoma cells
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
US7899623B2 (en) * 2004-09-22 2011-03-01 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CA3061785A1 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006052731A2 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
US20080118926A1 (en) * 2004-12-13 2008-05-22 National University Corporation Okayama University Method For Detecting Methylation In Genes And Method For Examining Neoplasm Through Detecting Methylation In Genes
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
WO2006090389A2 (en) 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2006110264A2 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JPWO2006101273A1 (ja) * 2005-03-25 2008-09-04 武田薬品工業株式会社 癌の予防・治療剤
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2006122295A2 (en) * 2005-05-11 2006-11-16 Expression Diagnostics, Inc. Methods of monitoring functional status of transplants using gene panels
CN101297045A (zh) 2005-06-03 2008-10-29 阿威亚拉德克斯股份有限公司 肿瘤和组织的鉴定
AU2006254874A1 (en) * 2005-06-08 2006-12-14 Carefusion 303, Inc. System and method for dynamic determination of disease prognosis
WO2007141595A2 (en) * 2005-11-10 2007-12-13 Aurelium Biopharma Inc. Method of diagnosing breast cancer using protein markers
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
JP2009536313A (ja) 2006-01-11 2009-10-08 レインダンス テクノロジーズ， インコーポレイテッド ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
CA2648580A1 (en) * 2006-04-07 2008-05-02 Xdx, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
US7789081B2 (en) * 2006-04-20 2010-09-07 Whirlpool Corporation Modular frame chassis for cooking range
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530168B1 (en) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Microfluidic Devices
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE602007013405D1 (de) * 2006-07-14 2011-05-05 Us Government Verfahren zur bestimmung der prognose eines adenokarzinoms
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US7993832B2 (en) * 2006-08-14 2011-08-09 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2090588A4 (en) 2006-10-23 2010-04-07 Neocodex S L IN VITRO PROCEDURE FOR THE PROGNOSIS AND / OR DIAGNOSIS OF OVER SENSITIVITY TO ESTROGENIC OR SUBSTANCES WITH ESTROGENIC EFFECT
KR100862972B1 (ko) 2006-10-30 2008-10-13 한국과학기술연구원 휘발성 유기 화합물 검색용 바이오마커 및 이를 이용한유해성을 나타내는 휘발성 유기 화합물 검색 방법
WO2008140484A2 (en) * 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
WO2008076447A2 (en) * 2006-12-15 2008-06-26 Ordway Research Institute Treatments of therapy-resistant diseases comprising drug combinations
RU2473555C2 (ru) * 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8030060B2 (en) * 2007-03-22 2011-10-04 West Virginia University Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
KR100886937B1 (ko) 2007-06-21 2009-03-09 주식회사 랩 지노믹스 유방암 및 난소암의 예측 또는 진단에 유용한 ｂｒｃａ1,ｂｒｃａ2 유전자 돌연변이
JP5303132B2 (ja) * 2007-09-20 2013-10-02 シスメックス株式会社 がん細胞の存否を判定する方法及び装置
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
WO2009124251A1 (en) * 2008-04-03 2009-10-08 Sloan-Kettering Institute For Cancer Research Gene signatures for the prognosis of cancer
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
EP2159291A1 (en) 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
EP2202320A1 (en) 2008-12-24 2010-06-30 Agendia B.V. Methods and means for typing a sample comprising colorectal cancer cells
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
EP3415235A1 (en) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation of microfluidic droplets
EP2241634A1 (en) * 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
WO2010123818A1 (en) * 2009-04-20 2010-10-28 Medical College Of Georgia Research Institute, Inc. Breast cancer susceptibility gene gt198 and uses thereof
US8637240B2 (en) * 2009-09-28 2014-01-28 Institute For Systems Biology Use of gene expression signatures to determine cancer grade
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
JP2013508835A (ja) * 2009-10-21 2013-03-07 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー バイオマーカー参照パターンを作成する方法
WO2011057125A2 (en) * 2009-11-05 2011-05-12 Myriad Genetics, Inc. Compositions and methods for determining cancer susceptibility
US20110123990A1 (en) * 2009-11-23 2011-05-26 Baker Joffre B Methods To Predict Clinical Outcome Of Cancer
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
JP6286124B2 (ja) 2010-01-11 2018-02-28 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
KR101773408B1 (ko) 2010-04-22 2017-08-31 도레이 카부시키가이샤 ａＲＮＡ의 조제방법 및 유전자 발현의 해석방법
JP5725274B2 (ja) 2010-04-22 2015-05-27 国立大学法人大阪大学 乳癌の予後の検査方法
EP3447155A1 (en) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwich assays in droplets
US20140031251A1 (en) * 2010-11-03 2014-01-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of classifying human subjects with regard to cancer prognosis
US10011876B2 (en) * 2010-11-23 2018-07-03 Krisani Biosciences Pvt. Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
BR112013018311A2 (pt) * 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
WO2012135845A1 (en) 2011-04-01 2012-10-04 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof
EP2714970B1 (en) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Enzyme quantification
US8748587B2 (en) 2011-06-02 2014-06-10 Novartis Ag Molecules and methods for modulating TMEM16A activities
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2723899B1 (en) * 2011-06-21 2020-11-18 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US9175351B2 (en) 2011-07-13 2015-11-03 Agendia N.V. Means and methods for molecular classification of breast cancer
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CN104080924A (zh) * 2011-08-16 2014-10-01 昂科赛特公司 用于治疗和诊断乳腺癌的方法和组合物
EP3495817A1 (en) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013155567A1 (en) * 2012-04-20 2013-10-24 Mat Malta Advanced Technologies Limited Sex determination genes
EP3524693A1 (en) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digital analyte analysis
US9045546B2 (en) 2012-05-31 2015-06-02 Novartis Ag Molecules and methods for modulating TMEM16A activities
CA2875710C (en) 2012-06-22 2021-06-29 John Wayne Cancer Institute Molecular malignancy in melanocytic lesions
EP2894477A4 (en) * 2012-09-05 2016-07-20 Wako Pure Chem Ind Ltd METHOD FOR DETECTION OF BREAST CANCER
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
JP2016521979A (ja) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
EP3014505A4 (en) * 2013-06-28 2017-03-08 Nantomics, LLC Pathway analysis for identification of diagnostic tests
AU2014318499B2 (en) 2013-09-16 2019-05-16 Biodesix, Inc Classifier generation method using combination of mini-classifiers with regularization and uses thereof
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US20170058351A1 (en) 2013-11-28 2017-03-02 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Methods for Molecular Classification of BRCA-Like Breast and/or Ovarian Cancer
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
US10370719B2 (en) * 2014-11-12 2019-08-06 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
US10980519B2 (en) 2015-07-14 2021-04-20 Duke University Systems and methods for extracting prognostic image features
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US11530448B2 (en) 2015-11-13 2022-12-20 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
US10821094B2 (en) 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10934590B2 (en) 2016-05-24 2021-03-02 Wisconsin Alumni Research Foundation Biomarkers for breast cancer and methods of use thereof
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3730941A1 (en) * 2019-04-23 2020-10-28 Institut Jean Paoli & Irène Calmettes Method for determining a reference tumor aggressiveness molecular gradient for a pancreatic ductal adenocarcinoma
EP4143344A1 (en) 2020-04-27 2023-03-08 Agendia N.V. Treatment of her2 negative, mammaprint high risk 2 breast cancer
WO2022029489A1 (en) 2020-08-06 2022-02-10 Agendia NV Systems and methods of using cell-free nucleic acids to tailor cancer treatment
US20220042108A1 (en) 2020-08-06 2022-02-10 Agendia NV Systems and methods of assessing breast cancer
CN112927795B (zh) * 2021-02-23 2022-09-23 山东大学 基于bagging算法的乳腺癌预测系统
WO2023224487A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Prediction of response to immune therapy in breast cancer patients
WO2023224488A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Dna repair signature and prediction of response following cancer therapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) * 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US6342491B1 (en) * 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US5677125A (en) * 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5578832A (en) * 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
EP1505159B1 (en) * 1995-03-17 2008-05-28 John Wayne Cancer Institute Detection of breast metastases with a multiple marker assay
WO1997020931A1 (en) * 1995-12-08 1997-06-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method and compositions for monitoring dna binding molecules in living cells
WO1998033450A1 (en) 1997-01-31 1998-08-06 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e
US6028189A (en) * 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
NO972006D0 (no) * 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US6432707B1 (en) * 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6107034A (en) * 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7648826B1 (en) * 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
AU6213600A (en) 1999-07-16 2001-02-05 Rosetta Inpharmatics, Inc. Methods for determining the specificity and sensitivity of oligonucleotides for hybridization
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU2596901A (en) 1999-12-21 2001-07-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001278070A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Basal cell markers in breast cancer and uses thereof
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
WO2002085298A2 (en) 2001-04-20 2002-10-31 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
WO2005008213A2 (en) * 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2558808A1 (en) 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
AU2005267756A1 (en) 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
JP2008536094A (ja) 2005-02-04 2008-09-04 ロゼッタ インファーマティクス エルエルシー 乳癌患者における化学療法反応性を予測する方法

Also Published As

Publication number Publication date
US7863001B2 (en) 2011-01-04
PT1410011E (pt) 2011-07-25
ATE503023T1 (de) 2011-04-15
WO2002103320A3 (en) 2003-07-31
US9909185B2 (en) 2018-03-06
US20090157326A1 (en) 2009-06-18
JP2009131262A (ja) 2009-06-18
WO2002103320A2 (en) 2002-12-27
US20030224374A1 (en) 2003-12-04
US7514209B2 (en) 2009-04-07
EP1410011A2 (en) 2004-04-21
EP1410011B1 (en) 2011-03-23
EP1410011A4 (en) 2007-08-01
US20130116145A1 (en) 2013-05-09
AU2002316251A1 (en) 2003-01-02
CA2451074A1 (en) 2002-12-27
US20180305768A1 (en) 2018-10-25
JP2005500832A (ja) 2005-01-13
DE60239535D1 (de) 2011-05-05
CA2451074C (en) 2014-02-11
DK1410011T3 (da) 2011-07-18
US20110301048A1 (en) 2011-12-08
JP5237076B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
CY1111677T1 (el) Διαγνωση και προγνωση ασθενων με καρκινο μαστου
WO2004065545A3 (en) Diagnosis and prognosis of breast cancer patients
Bläker et al. The association between mutations in BRAF and colorectal cancer–specific survival depends on microsatellite status and tumor stage
WO2006015312A3 (en) Prognosis of breast cancer patients
Sun et al. RETRACTED: comprehensive analysis of the expression and prognosis for E2Fs in human breast cancer
Park et al. Notch3 gene amplification in ovarian cancer
Li et al. BRAF mutation in papillary thyroid carcinoma
Huang et al. Epigenetics in breast cancer: what's new?
Schlomm et al. Clinical significance of p53 alterations in surgically treated prostate cancers
Frattini et al. Different genetic features associated with colon and rectal carcinogenesis
Cheuk et al. Detection of methylated circulating DNA as noninvasive biomarkers for breast cancer diagnosis
Casadio et al. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach
Li et al. Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients
Sushma et al. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population
Fernandez-Retana et al. Gene signature based on degradome-related genes can predict distal metastasis in cervical cancer patients
Eyvazi et al. CpG islands methylation analysis of CDH11, EphA5, and HS3ST2 genes in gastric adenocarcinoma patients
Rubin et al. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer
Zolotov Genetic testing in differentiated thyroid carcinoma: Indications and clinical implications
Aksenenko et al. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma
Misawa et al. 5-Hydroxymethylcytosine and ten-eleven translocation dioxygenases in head and neck carcinoma
Cabarcas-Petroski et al. A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma
Dong et al. Increased EXT1 gene copy number correlates with increased mRNA level predicts short disease-free survival in hepatocellular carcinoma without vascular invasion
Pasche et al. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment
Liao et al. Relationship between LINC00341 expression and cancer prognosis
Schrijver et al. Promoter hypermethylation profiling of distant breast cancer metastases